NEW YORK, July 28 (GenomeWeb News) - Invitrogen today reported a 21 percent increase in second-quarter revenue year over year, but a 24 percent drop in net earnings due to a one-time charge.

The Carlsbad, Calif.-based firm reported revenue of $306.5 million compared with $254 million in the second quarter last year. The company also beat analysts' consensus estimate of $301 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.